Gilead Sciences, Inc. (United States) holds 3 active US FDA Type II Drug Master Files and 4 inactive, has DMF or CEP filings on record for 2 active ingredients and is linked to 2 FDA-registered manufacturing sites. 40 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Gilead Sciences, Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/gilead-sciences-inc

Overview

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. With a portfolio of drugs in various stages of development, the company is known for its work in the fields of HIV, liver diseases, and cancer.

Core services & business areas

Pharmaceutical DistributionSupply Chain ManagementRegulatory Affairs

Therapeutic areas

HIV/AIDSLiver diseasesCancerInflammatory diseasesRespiratory diseases

Active ingredients with DMF or CEP filings

Substances for which Gilead Sciences, Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Gilead Sciences, Inc. holds 3 active (7 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • COBICISTAT ON SILICON DIOXIDEActive2011-10-24
  • ELVITEGRAVIRActive2011-10-21
  • AMBISOME, LIPOSOMAL AMPHOTERICIN BActive1992-03-06
  • LIPOSOMAL LURTOTECAN FOR INJECTION (OSI-211)Inactive2002-11-06
  • LIPOSOMAL OSI-7904 FOR INJECTION (OSI-7904L)Inactive2002-06-28
  • FK506LC AND PLACEBOInactive2001-10-12
  • PMPA GELInactive1997-10-07

Registered manufacturing sites (2)

Physical sites registered with the US FDA and resolved to Gilead Sciences, Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

40 FDA enforcement records linked to this company.

  • 4832026-02-18

    Procedures not in writing, fully followed

  • 4832026-02-18

    Reserve samples identified, representative, stored

  • 4832026-02-18

    Annual visual exams of drug products

  • 4832026-02-18

    Procedures for sterile drug products

  • 4832026-02-18

    Scientifically sound laboratory controls

  • 4832026-02-18

    Following/documenting laboratory controls

  • 4832026-02-18

    Sterility/pyrogens - test methods written, followed

  • recall — Class I2024-10-09

    Presence of Particulate Matter: Presence of glass particle.

  • 4832024-01-22

    Late submission of 15-day report

  • recall — Class I2022-01-05

    Presence of Particulate Matter: investigation into a customer complaint confirmed the presence of glass particulates.

  • 4832021-12-17

    Validation lacking for sterile drug products

  • 4832021-12-17

    Training , Education , Experience overall

  • 4832021-12-17

    Procedures not in writing, fully followed

  • 4832021-12-17

    Buildings not maintained in good state of repair

  • 4832018-07-17

    Late submission of 15-day report

  • recall — Class II2014-11-05

    Defective Container; leaking around the cap

  • recall — Class III2014-10-15

    Presence of Foreign Substance: Truvada was found to contain small red silicone rubber particulates.

  • 4832014-05-16

    Theoretical yield statement including percentages

  • 4832014-05-16

    Investigations of discrepancies, failures

  • 4832014-05-16

    Procedures not in writing, fully followed

  • 4832014-05-16

    Air Supply

  • 4832014-05-16

    Complete instructions, procedures, specifications et. al.

  • 4832014-05-16

    Deviations from laboratory control requirements

  • 4832014-05-16

    Unlabeled filled containers controls

  • 4832014-05-16

    Reprocessing procedures lack steps to be taken

  • recall — Class III2014-03-05

    Presence of Foreign Substance: Red Silicone Rubber Particulates are Present in Drug.

  • 4832014-01-15

    Late submission of 15-day report

  • recall — Class II2013-07-31

    Lack of Sterility Assurance; During a routine simulation of the manufacturing of AmBisome, a bacterial contamination was detected in some media fill units. No contaminated batches have actually been identified in the finished product, but there is a possibility of contamination.

  • recall — Class I2013-05-22

    Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).

  • warning_letter2010-09-21

    FDA Warning Letter (drug product)

  • 4832010-02-12

    Review of representative number of batches

  • 4832010-02-12

    Cleaning / Sanitizing / Maintenance

  • 4832010-02-12

    Scientifically sound laboratory controls

  • 4832010-02-12

    Procedures for sterile drug products

  • 4832010-02-12

    Acceptance criteria for sampling & testing

  • 4832010-02-12

    Validation lacking for sterile drug products

  • 4832010-02-12

    Equipment to control conditions

  • 4832010-02-12

    Buildings not maintained in good state of repair

  • 4832010-02-12

    Aseptic Processing Area

  • 4832010-02-12

    Environmental Monitoring System

For suppliers

Is this Gilead Sciences, Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.